Recombinant adeno-associated virus for muscle directed gene therapy
Author: ["Krishna J. Fisher","Karin Jooss","James Alston","Yiping Yang","Sarah Ehlen Haecker","Katherine High","Ravindra Pathak","Steven E. Raper","James M. Wilson"]
Publication: Nature Medicine
CITE.CC academic search helps you expand the influence of your papers.
Abstract
Although gene transfer with adeno-associated virus (AAV) vectors has typically been low, transduction can be enhanced in the presence of adenovirus gene products through the formation of double stranded, non-integrated AAV genomes. We describe the unexpected finding of high level and stable transgene expression in mice following intramuscular injection of purified recombinant AAV (rAAV). The rAAV genome is efficiently incorporated into nuclei of differentiated muscle fibers where it persists as head-to-tail concatamers. Fluorescent in situ hybridization of muscle tissue suggests single integration sites. Neutralizing antibody against AAV capsid proteins does not prevent readministration of vector. Remarkably, no humoral or cellular immune responses are elicited to the neoantigenic transgene product E. coli β-galactosidase. The favorable biology of rAAV in muscle-directed gene therapy described in this study expands the potential of this vector for the treatment of inherited and acquired diseases.
Cite this article
Fisher, K., Jooss, K., Alston, J. et al. Recombinant adeno-associated virus for muscle directed gene therapy. Nat Med 3, 306–312 (1997). https://doi.org/10.1038/nm0397-306
